iShares Biotechnology ETF
782 hedge funds and large institutions have $3.93B invested in iShares Biotechnology ETF in 2025 Q2 according to their latest regulatory filings, with 57 funds opening new positions, 136 increasing their positions, 342 reducing their positions, and 82 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
782
Holders Change
-39
Holders Change %
-4.75%
% of All Funds
10.49%
Holding in Top 10
7
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-12.5%
% of All Funds
0.09%
New
57
Increased
136
Reduced
342
Closed
82
Calls
$216M
Puts
$168M
Net Calls
+$47.6M
Net Calls Change
+$385M
Top Buyers
| 1 |
Goldman Sachs
New York
|
+$247M |
| 2 |
Citigroup
New York
|
+$110M |
| 3 |
Morgan Stanley
New York
|
+$103M |
| 4 |
JPMorgan Chase & Co
New York
|
+$44.9M |
| 5 |
ERSOT
Employees Retirement System of Texas
Austin,
Texas
|
+$25M |
Top Sellers
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$105M |
| 2 |
MMEA
Main Management ETF Advisors
San Francisco,
California
|
-$78.3M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
-$57.2M |
| 4 |
Barclays
London,
United Kingdom
|
-$41.8M |
| 5 |
Two Sigma Investments
New York
|
-$35.5M |
